Hepatocellular carcinomas (HCCs) vary in their macroscopic appearances, from well-circumscribed expansile nodules to those with multinodular features and irregular margins; however, the gross classification of HCC has not received much attention in the literature. Although the macroscopic classification was first described by Eggel in 1901 based on an autopsy series, it was not until the late 1980's that the gross classification was proposed and adopted by the Liver Cancer Study Group of Japan (LCSGJ) in the General Rules of the Clinical and Pathologic Study of Primary Liver Cancer \[[@b1-jptm-2017-11-13],[@b2-jptm-2017-11-13]\]. Since then, there have been several clinicopathological studies that focused on the gross features of HCC, mainly from Asian countries, and most studies have demonstrated that HCCs with single nodular morphology have more favorable outcomes compared with those with multinodular or infiltrative (INF) growth patterns \[[@b3-jptm-2017-11-13]-[@b11-jptm-2017-11-13]\]. As the gross appearance of HCCs can be recognized preoperatively by imaging studies, it could have translational impact on clinical practice, such as guiding treatment decisions. However, the gross appearance was only reflected in the Cancer of the Liver Italian Program (CLIP) score (uninodular versus multinodular) which is not deemed suitable for the current population of HCC patients \[[@b12-jptm-2017-11-13]\], and the current widely used staging systems, such as the modified Union for International Cancer Control (UICC), Barcelona Clinic Liver Cancer (BCLC), and American Joint Committee on Cancer (AJCC) TNM classifications focus on the multiplicity, size and vascular/bile duct invasion status of the HCCs.

In this study, we analyzed the differences in the clinicopathological features and survival between the different gross morphological types of HCC in a single cohort of surgically resected solitary HCCs. The gross morphology was classified according to The General Rules for the Study of Primary Liver Cancer published by the Korean Liver Cancer Association (KLCA) \[[@b13-jptm-2017-11-13]\].

MATERIALS AND METHODS
=====================

Patient selection and clinicopathological analysis
--------------------------------------------------

Two hundred and ninety-eight consecutive cases of primary HCCs that were surgically resected between 2003 and 2012 at Seoul National University Bundang Hospital, Seongnam, Republic of Korea were evaluated in this study. This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-1708-412-304), and patient consent was waived due to the retrospective nature of this study. Clinicopathological data were analyzed by reviewing electronic medical records, pathology reports and glass slides, and included patient sex, age at operation, tumor size, gross type, histologic differentiation (Edmondson-Steiner grade), serum α-fetoprotein (AFP) levels and the pathological T and N categories according to AJCC TNM staging system (7th edition). The presence of intratumoral fibrous stroma was also noted; we defined the presence of intratumoral fibrous stroma as fibrous stroma occupying more than 30% of the tumor area \[[@b14-jptm-2017-11-13]\]. Cases with multiple HCCs were excluded from the study, leaving a total of 242 cases for further analysis. Follow-up data was retrieved from the electronic medical records, including the status at last follow up and occurrence of distant or intrahepatic metastasis or local recurrence.

The gross type was determined by examining the largest cross section of the tumor by two pathologists (Y.L. and H.K.), according to the General Rules for the Study of Primary Liver Cancer by the KLCA ([Fig. 1](#f1-jptm-2017-11-13){ref-type="fig"}) \[[@b13-jptm-2017-11-13]\]. "Vaguely nodular" (VN) type was defined as a nodule with indistinct margins. While VN type morphology is an important characteristic of early HCC \[[@b15-jptm-2017-11-13]\], we classified HCCs as VN type purely by gross appearance, regardless of the tumor size and histologic differentiation status. "Expanding nodular" (EN) type was defined by as a round expansile nodule with a distinct margin. "Multinodular confluent" (MC) type was defined as a cluster of small and confluent nodules. "Nodular with perinodular extension" (NP) type was defined as an expanding nodule similar to EN type HCCs that had extranodular growth in less than 50% of the tumor circumference. INF type HCCs showed extranodular growth in more than 50% of the tumor circumference. The gross types were correlated with the clinicopathological features of the HCCs.

Tissue microarray construction and immunohistochemistry
-------------------------------------------------------

Two-millimeter-core tissue microarrays were constructed from the HCCs (Superbiochips Laboratories, Seoul, Korea), and 4 μm-thick tissue sections obtained from the tissue microarray blocks. Immunohistochemical staining was performed for "stemness"-related markers (cytokeratin 19 \[CK19\]; 1:100, mouse monoclonal, Dako, Glostrup, Denmark), epithelial cell adhesion molecule (EpCAM; 1:3,000, mouse monoclonal, Millipore, Billerica, MA, USA), and epithelial-mesenchymal transition (EMT)--related markers (urokinase plasminogen activator receptor \[uPAR; 1:40, mouse monoclonal, Abcam, Cambridge, UK\] and ezrin \[1:100, mouse monoclonal, Abcam\]). Briefly, after deparaffinization in xylene and rehydration in graded alcohol, antigen retrieval was performed on tissue sections using citrate buffer (pH 6.0) for CK19, EpCAM, and ezrin, and protease for uPAR. Incubation with primary antibodies was performed for 1 hour at room temperature, and with secondary antibody (EnVision kit, Dako) for 30 minutes. The presence of cytoplasmic expression in \> 5% of the tumor cells was regarded as positive for CK19, ezrin, and uPAR expression. EpCAM was expressed in the tumor cell membranes.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS ver. 19.0 K (SPSS Korea, Seoul, Korea). Chi-square tests and Fisher exact tests were performed as deemed appropriate. Survival analyses for overall and disease-free survivals were performed by the Kaplan-Meier method and log-rank test. The Cox regression models were used for multivariate analysis. Statistical significance was defined as p \< .05.

RESULTS
=======

Clinicopathological characteristics according to HCC gross classification
-------------------------------------------------------------------------

The clinicopathological characteristics of the 242 cases studied are summarized in [Table 1](#t1-jptm-2017-11-13){ref-type="table"}. The most common etiologic factor was hepatitis B virus (HBV) infection (171/242, 70.7%), followed by alcohol (35/242, 14.5%), hepatitis C virus (HCV) infection (17/242, 7.0%) and combined HBV + HCV infection (1/242, 0.4%). The etiology was uncertain for the remainder of patients (18/298, 7.4%). The most common gross type of HCCs was the EN type (107/242, 44.2%), followed by the MC type (78/242, 32.2%), NP type (32/242, 13.2%), INF type (16/242, 6.6%), and the VN type (9/242, 3.7%).

When the clinicopathological features were compared among the five different gross types, we found that INF type HCCs were associated with larger tumor size, poor histologic differentiation, more frequent microvascular and portal venous invasion and higher pathologic T stage compared to the other gross types ([Table 2](#t2-jptm-2017-11-13){ref-type="table"}). Large tumor size, microvascular and portal venous invasion and high T stage were rare or absent in VN or EN type HCCs. The clinicopathological features of MC and NP type HCCs were similar. We regrouped the five gross types into type 1 and type 2, as previously described by Gong *et al*. \[[@b5-jptm-2017-11-13]\]: type 1 HCCs consisted of VN and EN type, and type 2 HCCs consisted of MC, NP, and INF types. On comparing the clinicopathological findings between the two types, we found that type 2 HCCs were more frequently larger (p \< .001) and poorly differentiated (p = .001), and showed more frequent microvascular invasion (p \< .001), portal venous invasion (p \< .001), higher pT stages (p \< .001), and intratumoral fibrous stroma (p \< .001) compared to type 1 HCCs.

Differences in expression status of "stemness"- and EMT-related markers in HCC according to gross classification
----------------------------------------------------------------------------------------------------------------

The immunohistochemical stain results are summarized in [Table 2](#t2-jptm-2017-11-13){ref-type="table"} and [Fig. 2](#f2-jptm-2017-11-13){ref-type="fig"}. The expression of "stemness"-related markers, CK19 and EpCAM, was seen in 18.6% and 43.4% of HCCs, respectively. CK19 and EpCAM expression rates were significantly higher in INF type HCCs compared to EN type HCCs (CK19, 37.5% vs 9.3%; EpCAM, 75.0% vs 34.6%). Significant differences were seen in the frequencies of CK19 and EpCAM positivity between type 1 and type 2 HCCs (CK19, p = .002; EpCAM, p = .009). uPAR and ezrin, EMT-related markers, were more frequently expressed in type 2 HCCs compared to type 1 HCCs (uPAR, p \< .001; ezrin, p = .036).

Survival analysis results
-------------------------

Of the five different gross types, the INF type demonstrated the worst overall survival (p = .015) and disease-free survival (p=.034) compared to other types ([Table 3](#t3-jptm-2017-11-13){ref-type="table"}, [Fig. 3](#f3-jptm-2017-11-13){ref-type="fig"}). The most favorable outcome was seen for EN and VN types, and the survival curves for MC and NP types were in between that of EN and INF type HCCs. When the gross types were simplified into two groups, type 2 HCCs showed significantly decreased disease-free (p = .015) and overall survival (p = .003) compared to type 1 HCCs. Of the other clinicopathological variables, tumor size of larger than 5 cm was associated with a decreased disease-free survival (p = .041), portal venous invasion (p \< .001) and higher pT stage (p \< .001) were associated with decreased overall survival, and microvascular invasion was marginally associated with decreased disease-free and overall survivals although not statistically significant.

Multivariate analysis demonstrated that gross classification (type 1 vs 2) was a significant independent predictor of both overall and disease-free survival, after adjusting for patient sex and age. Type 2 HCCs showed significantly decreased overall survival (p = .030; hazard ratio, 4.118; 95% confidence interval, 1.142 to 14.844) and disease-free survival (p = .016; hazard ratio, 1.617; 95% confidence interval, 1.092 to 2.394). High pathologic T stage also remained a significant predictive factor for overall survival (p = .025; hazard ratio, 3.173; 95% confidence interval, 1.156 to 8.710).

DISCUSSION
==========

In this study, we found that INF type HCCs had the worst prognosis out of the five different gross types, and when the HCCs were further grouped into types 1 and 2, gross type 2 HCCs more frequently showed clinicopathological features of aggressive behavior and poor prognosis compared to type 1 HCCs. The gross classification had a strong impact on patient survival; type 2 gross morphology was a significant independent predictor of decreased overall and disease-free survivals on multivariate analysis.

Our findings are similar to the results of a few previous studies. Increased overall and disease-free survival was noted for single nodular type HCCs compared to those with extranodular growth or MC growth patterns \[[@b6-jptm-2017-11-13],[@b9-jptm-2017-11-13]\]. Interestingly, Shimada *et al*. \[[@b9-jptm-2017-11-13]\] analyzed small HCCs (\< 3 cm) separately and found similar associations between gross morphology and prognosis, and in another analysis \[[@b3-jptm-2017-11-13]\] on huge HCCs (\> 10 cm), single nodular type HCCs showed more favorable outcomes compared to non-single nodular HCCs. Taken together, it could be suggested that the gross classification may be an important predictor of prognosis regardless of tumor size. When tumor size was entered into our multivariate analysis model, we found that gross type 2 was a strong independent predictor of both overall survival and disease-free survival.

The gross classification consists of five different morphological types of HCCs and clear definitions for the different types have been proposed in the guidelines of both the LCSGJ and KLCA. However, in practice, the distinction between NP, MC, and INF type HCCs is not always clear cut, and prone to interobserver variability. On the other hand, EN and VN types (known as "single nodular with distinct margin" and "single nodular with indistinct margin" types in the LCSGJ guidelines, respectively) are relatively easier to discriminate from the other types as they lack the multilobulated irregular contour. If the gross classification is an important prognostic factor for HCC on surgically resected specimens, this could also be implemented in the preoperative evaluation of HCC patients, as the gross features can be determined on preoperative imaging. Therefore, it may be sufficient and more practical to classify HCCs as single nodular types (type 1) and non-single nodular types (type 2) for guiding patient management strategies. Interestingly, Fu *et al*. \[[@b4-jptm-2017-11-13]\] analyzed the survival of patients with small HCCs (\< 5 cm) treated with radiofrequency ablation according to the gross type on imaging, and found that HCCs with single nodular HCCs without extranodular growth or irregular margins were associated with favorable survival.

A subset of HCCs that have morphological features consistent with HCC have been demonstrated to express immunophenotypes associated with "stemness," such as CK19, EpCAM, CD133, and c-kit positivity. These tumors have been associated with higher preoperative serum AFP levels, less frequent fibrous capsule formation, intratumoral fibrous stroma, frequent vascular invasion and poor prognosis compared to typical HCCs that do not express these markers \[[@b16-jptm-2017-11-13],[@b17-jptm-2017-11-13]\]. As expected, we found in this study that larger tumor size, poor histological differentiation, microvascular and portal venous invasion, intratumoral fibrous stroma, "stemness" and EMT-related marker expression and higher T stages were significantly more frequent in type 2 HCCs compared to type 1 HCCs. Therefore, HCCs that have a solitary, well-circumscribed and expansile growth pattern were less likely to exhibit features associated with "stemness." The higher prevalence of CK19 expression in type 2 HCCs has been recently demonstrated by another group \[[@b5-jptm-2017-11-13]\].

EMT refers to the process in which tumor epithelial cells lose their epithelial characteristics (e.g., loss of membranous E-cadherin expression) and acquire mesenchymal features, facilitating tumor invasion and distant metastasis \[[@b18-jptm-2017-11-13]\]. This process has been described in HCCs, and HCCs expressing ezrin and uPAR have been associated with poor prognoses \[[@b19-jptm-2017-11-13],[@b20-jptm-2017-11-13]\]. We found in this study that INF type HCCs showed frequent uPAR expression (75%) compared to other types, especially VN and EN types which were uPAR positive in 11% and 15%, respectively. MC and NP types showed uPAR expression frequency intermediate between INF types and EN/VN types. In a previous study from Japan, E-cadherin loss was more frequently seen in single nodular with extranodal growth type and confluent multinodular type HCCs of less than 6 cm in diameter (which can be translated to NP and MC type HCCs according to the KLCA classification) \[[@b7-jptm-2017-11-13]\]. Taken together, it could be suggested that invasiveness and metastatic ability of HCCs could be reflected by the gross appearance.

On examining the Kaplan-Meier curves for overall and disease-free survival according to the five different gross types of our cohort, significant differences in survival were noted between the EN types and INF types. The MC and NP types showed survivals intermediate between the EN and INF types, without significant differences between the two types. Interestingly, while the VN type showed the best overall survival (no HCC-related deaths), early recurrences were noted for two VN type HCCs (at 17 and 18 months) for the disease-free survival analysis. Although VN type morphology is a characteristic feature of early HCC \[[@b15-jptm-2017-11-13]\], we included all cases that were macroscopically of VN type regardless of the histological differentiation or tumor size; indeed, poor histological differentiation was noted in 4/9 (44.4%) cases and 2/9 (22.2%) cases were larger than 3 cm. Therefore, the VN type in this study does not refer to early HCC, and we grouped VN and EN types together into type 1 (single nodular) HCCs for analytical purposes.

Although this is not the first report on the clinicopathological significance of the gross classification of HCCs, this is a large-scale cohort study of 242 surgically resected solitary HCCs using the definitions in the guidelines of the KLCA, and we also demonstrate for the first time the associations between the different gross types and the expression status of "stemness"- and EMT-related markers. A limitation of this study is that we excluded multiple HCCs (including multicentricity and intrahepatic metastasis) from the study cohort in order to exclude cases showing multiple gross types in the same liver. This resulted in the lower percentage of cases with higher pT stage, and the exclusion of pT3a cases using the current AJCC staging system (seventh edition). Nevertheless, we demonstrate that the gross classification of HCCs according to the KLCA guidelines has prognostic value, and that gross type 2 HCCs with non-single nodular patterns are associated with clinicopathological features of aggressive behavior, increased expression of "stemness"- and EMT-related markers and decreased survival. Further validation would be required in independent cohorts and also radio-pathological correlation studies would be needed to validate the utility of the gross classification in HCC patient management.
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![Examples of the different gross types of hepatocellular carcinoma. (A) Vaguely nodular type. (B) Expanding nodular type. (C) Multinodular confluent type. (D) Nodular with perinodular extension type. (E) Infiltrative type.](jptm-2017-11-13f1){#f1-jptm-2017-11-13}

![Immunohistochemical stain results for stemness- and epithelial-mesenchymal transition-related markers: cytokeratin 19 (A), epithelial cell adhesion molecule (B), and ezrin (C).](jptm-2017-11-13f2){#f2-jptm-2017-11-13}

![Kaplan-Meier curves demonstrating differences in disease-free survival and overall survival according to gross classification of hepatocellular carcinoma. (A, B) Disease-free survival. (C, D) Overall survival. VN, vaguely nodular; EN, expanding nodular; MC, multinodular confluent; NP, nodular with perinodular extension; INF, infiltrative.](jptm-2017-11-13f3){#f3-jptm-2017-11-13}

###### 

Summary of the clinicopathological characteristics

  Characteristic                                        No. (%) (n = 242)
  ----------------------------------------------------- -------------------
  Sex                                                   
   Male                                                 181 (74.8)
   Female                                               61 (25.2)
  Age at operation, median (range, yr)                  59 (29-87)
  Preoperative serum AFP level, median (range, ng/mL)   14.35 (1--40,000)
  Etiology                                              
   Hepatitis B virus (HBV)                              171 (70.7)
   Alcohol                                              35 (14.5)
   Hepatitis C virus (HCV)                              17 (7.0)
   HBV + HCV                                            1 (0.4)
   Uncertain etiology                                   18 (7.4)
  Tumor size, median (range, cm)                        3.0 (0.9--17.0)
   ≤ 2                                                  52 (21.5)
   \> 2 and ≤ 5                                         145 (59.9)
   \> 5                                                 45 (18.6)
  Gross type                                            
   Vaguely nodular                                      9 (3.7)
   Expanding nodular                                    107 (44.2)
   Multinodular confluent                               78 (32.2)
   Nodular with perinodular extension                   32 (13.2)
   Infiltrative                                         16 (6.6)
  Edmondson-Steiner grade                               
   Grade I                                              2 (0.8)
   Grade II                                             74 (30.6)
   Grade III                                            142 (58.7)
   Grade IV                                             24 (9.9)
  Microvascular invasion                                
   Absent                                               154 (63.6)
   Present                                              88 (36.4)
  Portal vein invasion                                  
   Absent                                               225 (93.0)
   Present                                              17 (7.0)
  Cirrhosis in background liver                         
   Absent                                               109 (45.0)
   Present                                              126 (52.1)
  Intratumoral fibrous stroma (\> 30%)                  
   Absent                                               187 (77.3)
   Present                                              55 (22.7)
  Pathologic T category (AJCC 7th edition)              
   pT1                                                  140 (57.9)
   pT2                                                  82 (33.9)
   pT3                                                  17 (7.0)
   pT4                                                  3 (1.2)
  Pathologic N category (AJCC 7th edition)              
   pN0                                                  240 (99.2)
   pN1                                                  2 (0.8)
  Recurrence on follow-up                               
   Absent                                               138 (57.0)
   Present                                              104 (43.0)
  Status at last follow-up                              
   Alive                                                160 (66.1)
   Deceased of disease                                  19 (7.9)
   Deceased of other cause                              5 (2.1)
   Follow-up loss                                       58 (24.0)

AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer.

###### 

Clinicopathological features and immunohistochemical stain results according to gross type

                                   VN (n = 9)   EN (n = 107)   MC (n = 78)   NP (n = 32)   INF (n = 16)   Type 1 (VN, EN) (n = 116)   Type 2 (MC, NP, INF) (n = 126)   p-value (type 1 vs 2)
  -------------------------------- ------------ -------------- ------------- ------------- -------------- --------------------------- -------------------------------- -----------------------
  Tumor size (\> 5 cm)             0            11 (10.3)      21 (26.9)     7 (21.9)      6 (37.5)       11 (9.5)                    34 (27.0)                        \< .001
  HBV etiology                     5 (55.6)     73 (68.2)      58 (74.4)     21 (65.6)     15 (93.8)      78 (67.2)                   94 (74.6)                        .207
  Edmondson-Steiner grade III/IV   4 (44.4)     64 (59.8)      58 (74.4)     25 (78.1)     15 (93.8)      68 (58.6)                   98 (77.8)                        .001
  Microvascular invasion           1 (11.1)     29 (27.1)      34 (43.6)     14 (43.8)     10 (62.5)      30 (25.9)                   58 (46.0)                        \< .001
  Portal vein invasion             0            0              4 (5.1)       5 (15.6)      8 (50.0)       0                           17 (13.55)                       \< .001
  High T category (pT3 or pT4)     0            1 (0.9)        7 (9.0)       5 (15.6)      7 (43.8)       1 (0.9)                     19 (15.1)                        \< .001
  Cirrhosis in background liver    6 (66.7)     49 (46.7)      42 (57.5)     15 (46.9)     14 (87.5)      55 (48.2)                   71 (58.1)                        .118
  Serum AFP level \> 1,000 ng/mL   0            12 (13.6)      10 (14.7)     6 (20.7)      6 (37.5)       12 (12.6)                   22 (19.5)                        .194
  Fibrous stroma (\> 30%)          1 (11.1)     14 (13.1)      25 (32.1)     9 (28.1)      6 (37.5)       15 (12.9)                   40 (31.7)                        \< .001
  CK19 positive                    2 (22.2)     10 (9.3)       20 (25.6)     7 (21.9)      6 (37.5)       12 (10.3)                   33 (26.2)                        .002
  EpCAM positive                   3 (33.3)     37 (34.6)      34 (43.6)     19 (59.4)     12 (75.0)      40 (34.5)                   65 (51.6)                        .009
  uPAR positive                    1 (11.1)     16 (15.2)      22 (28.2)     14 (43.8)     12 (75.0)      17 (14.9)                   48 (38.1)                        \< .001
  Ezrin positive                   4 (44.4)     34 (32.4)      40 (51.3)     12 (37.5)     7 (43.8)       38 (33.3)                   59 (46.8)                        .036

VN, vaguely nodular; EN, expanding nodular; MC, multinodular confluent; NP, nodular with perinodular extension; INF, infiltrative; HBV, hepatitis B virus; AFP, α-fetoprotein; CK19, cytokeratin 19; EpCAM, epithelial cell adhesion molecule; uPAR, urokinase plasminogen activator receptor.

###### 

Survival analysis results

  Variable                                                                         Overall survival        Disease-free survival                          
  -------------------------------------------------------------------------------- ----------------------- ----------------------- ---------------------- ------
  Univariate analysis                                                                                                                                     
  Gross type (type 1 vs type 2)^[a](#tfn1-jptm-2017-11-13){ref-type="table-fn"}^   5.439 (1.583--18.683)   .007                    1.617 (1.092--2.394)   .016
  Tumor size (\> 5 cm)                                                             1.229 (0.407--3.712)    .714                    1.590 (1.013--2.495)   .044
  High E-S grade (III or IV)                                                       0.636 (0.256--1.583)    .331                    1.054 (0.694--1.599)   .805
  Microvascular invasion                                                           2.178 (0.881--5.383)    .092                    1.445 (0.977--2.138)   .065
  Portal vein invasion                                                             5.311 (1.906--14.796)   \< .001                 1.702 (0.858--3.376)   .128
  High T category (pT3 or pT4)                                                     5.206 (1.974--13.728)   \< .001                 1.795 (0.982--3.284)   .057
  Intratumoral stromal fibrosis                                                    2.037 (0.801--5.179)    .135                    0.973 (0.608--1.559)   .973
  Multivariate analysis                                                                                                                                   
  Gross type (type 1 vs type 2)                                                    4.118 (1.142--14.844)   .030                    1.617 (1.092--2.394)   .016
  Tumor size (\> 5 cm)                                                             0.586 (0.166--2.060)    .404                    1.303 (0.802--2.115)   .285
  Microvascular invasion                                                           1.953 (0.765--4.982)    .161                    1.300 (0.866--1.952)   .205
  Portal vein invasion                                                             1.091 (0.150--7.931)    .931                    0.954 (0.292--3.124)   .938
  High T category (pT3 or pT4)                                                     3.173 (1.156--8.710)    .025                    1.462 (0.500--4.275)   .487

E-S grade, Edmondson-Steiner grade.

Type 1: vaguely nodular and expanding nodular types, type 2: multinodular confluent, nodular with perinodular extension and infiltrative types.
